Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cediranib + Olaparib
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cediranib AZD-2171|Recentin|AZD2171|AZD 2171 KIT Inhibitor 55 VEGFR1 Inhibitor 5 VEGFR2 Inhibitor 36 VEGFR3 Inhibitor 6 Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417).
Olaparib Lynparza AZD2281|KU-0059436 PARP Inhibitor (Pan) 27 Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Completed USA 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT03278717 Phase III Olaparib Cediranib + Olaparib Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) Recruiting CAN 3
NCT02974621 Phase II Bevacizumab Cediranib + Olaparib Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT04487587 Phase II Cediranib + Olaparib A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) Unknown status 1
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Recruiting USA 0
NCT03741426 Phase II Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib WIRE - Novel Treatments in Renal Cell Cancer (WIRE) Recruiting 1
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT04090567 Phase II Cediranib + Olaparib Ceralasertib + Olaparib Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Recruiting USA 0
NCT02681237 Phase I Cediranib + Olaparib A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer Completed CAN 0
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 2
NCT02345265 Phase II Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT02893917 Phase II Cediranib + Olaparib Olaparib Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02899728 Phase II Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Terminated USA 0
NCT02340611 Phase II Cediranib + Olaparib A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib Completed CAN 0
NCT04739800 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Cediranib + Durvalumab Cediranib + Olaparib Cediranib + Durvalumab + Olaparib Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Recruiting USA 1


Additional content available in CKB BOOST